Northpointe's 15min chart shows Bollinger Bands Narrowing and Bearish Marubozu formation.

According to the 15-minute chart of Northpointe, the Bollinger Bands have narrowed and a bearish Marubozu pattern has emerged at 13:15 on October 8, 2025. This indicates a decrease in the magnitude of stock price fluctuations, suggesting that sellers currently control the market. As a result, there is a high likelihood of continued bearish momentum.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company, has seen a series of notable developments in recent weeks. These include regulatory milestones, strategic appointments, and significant financial activities. This article aims to provide a comprehensive overview of Invivyd's recent actions and their potential impact on the company's stock performance.

# Regulatory Milestones and Clinical Trials

Invivyd announced the receipt of U.S. FDA clearance for its Investigational New Drug (IND) application and alignment on the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody to prevent COVID-19. The company plans to conduct two trials, DECLARATION and LIBERTY, which are expected to start around year-end 2025 with top-line data anticipated mid-2026 Invivyd Stock Price, News & Analysis^[1].

# Strategic Appointments

The company has made strategic appointments to bolster its leadership and expertise. Dr. Paul B. Bolno, M.D., President and CEO of Wave Life Sciences, was appointed to Invivyd's Board of Directors and Compensation Committee. Additionally, Kristie Kuhl was appointed as Chief Communications Officer, joining from Zeno Group where she served as Global Managing Director of Health & Wellness [^2, 3].

# Financial Highlights

Invivyd has also undertaken significant financial activities. The company closed a public offering, raising $57.5 million in gross proceeds, and exercised its underwriter's option to purchase additional shares. The proceeds will support the VYD2311 clinical program, research in RSV and measles, and the SPEAR Study Group's efforts regarding Long COVID and COVID-19 Post-Vaccination Syndrome treatments .

# Market Outlook

Analysts have noted that the stock price of Invivyd (IVVD) has shown bearish momentum, with a narrow range indicated by Bollinger Bands and the emergence of a bearish Marubozu pattern on the 15-minute chart. This suggests that sellers currently control the market, leading to a high likelihood of continued bearish momentum .

# Conclusion

Invivyd's recent developments, including regulatory approvals, strategic appointments, and significant financial activities, indicate the company's commitment to advancing its pipeline of monoclonal antibody therapies for viral infectious diseases. However, the current market sentiment, as indicated by technical analysis, suggests a potential continued downward trend in stock price. Investors should closely monitor Invivyd's progress and the broader market conditions.

# References

Invivyd Stock Price, News & Analysis^[1] https://www.stocktitan.net/news/IVVD/
https://www.stocktitan.net/news/IVVD/09/24/2025
https://www.stocktitan.net/news/IVVD/09/17/2025
https://www.stocktitan.net/news/IVVD/08/22/2025
https://www.stocktitan.net/news/IVVD/08/18/2025